TCRT — Alaunos Therapeutics Cashflow Statement
0.000.00%
- $6.76m
- $2.61m
- $0.01m
Annual cashflow statement for Alaunos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -118 | -80 | -78.8 | -37.7 | -35.1 |
Depreciation | |||||
Non-Cash Items | 68.1 | 6.83 | 11.9 | 4.38 | 8.65 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 8.22 | 15 | 2.79 | 1.36 | -5.97 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -40.9 | -57 | -61.5 | -29.2 | -30.1 |
Capital Expenditures | -0.284 | -9.78 | -3.32 | -0.216 | -0.197 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | — | 0.023 | 1.54 |
Sale of Fixed Assets | |||||
Cash from Investing Activities | -0.284 | -9.78 | -3.32 | -0.193 | 1.35 |
Financing Cash Flow Items | — | — | -0.26 | 0 | -0.125 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 59.1 | 102 | 25.8 | 6.37 | -18.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 18 | 35.3 | -39 | -23.1 | -46.9 |